Oric Pharmaceuticals, Inc. ORIC
NASDAQ · United States · Health Technology
$13.03-0.44 (-3.27%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
On August 3, ORIC Pharmaceuticals (NASDAQ:ORIC) reported second-quarter results that showed a clinical-stage biotech converting years of early work into two separate late-stage bets at once. The company started Himalayas-1, a global Phase 3 trial of its lead prostate cancer drug rinzimetostat, while holding $387.6 million in cash and investments to fund the effort. That […]
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 1, 2026 (the “Grant Date”), ORIC granted a total of 39,200 non-qualified stock options and 6,400 restricted stock units to two new non-executive employees who began their employment with ORIC in August 2026. These inducement gra
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.